MIDDLE EAST AND ASIA PACIFIC BIOTECHNOLOGY MARKET ANALYSIS

Middle East and Asia Pacific Biotechnology Market, by Technology (Nanobiotechnology, Tissue Engineering and Regeneration, Fermentation, Cell Based Assay, CRISPR, and Others ), by Application (Molecular Biology, Gene Synthesis, Gene Editing, Mammalian Protein Expression, Recombinant Antibody Expression, Peptide Synthesis, Protein Expression, Monoclonal and Polyclonal Antibody Generation, and Others), by End User (Biotechnology & Pharmaceutical Companies, Research Institutes & Laboratories, Academic Institutions, and Others), and by Region (Asia Pacific and Middle East) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published In : Feb 2022
Code : CMI4937
Pages :415
Formats :
Excel and PDF
Industry : Biotechnology

Market Challenges And Opportunities

High cost associated with the use of biotechnology products

Growth Drivers:

Increasing cases of chronic diseases
Rising initiatives related to biosimilars by market players
Increasing research and development activities by market players

Restraint- Middle East and Asia Pacific Biotechnology Market

High cost of treatment using some biotechnology solutions like gene therapies is expected to act as a restraint for the Middle East and Asia Pacific biotechnology market growth over the forecast period. For instance, according to the data published by the Yale Journal of Biology and Medicine in December 2019, research and development in the field of gene therapies (a branch of biotechnology) is expensive and uncertain. The cost of conducting clinical trials is high for gene therapies and gaining success in the results of these clinical trials is highly uncertain. Moreover, stringent regulatory guidelines by authorities such as U.S. Food and Drug Administration (FDA) makes the process of obtaining approval for use of gene therapies difficult.